Metabolic dysfunction in obstructive sleep apnea: A critical examination of underlying mechanisms

Sleep and Biological Rhythms

Volumn 13, Issue 1, 2015, Pages 2-17

  Mesarwi, Omar A ^a   Sharma, Ellora V ^b   Jun, Jonathan C ^a   Polotsky, Vsevolod Y ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Hypoxia; Oxidative stress; Sleep fragmentation; Sympathetic nervous system

Indexed keywords

CATECHOLAMINE; GLUTATHIONE REDUCTASE; HYDROGEN PEROXIDE; NITRIC OXIDE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ADIPOSE TISSUE; ADRENERGIC SYSTEM; ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; ELEVATED BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HUMAN; HYPERCAPNIA; HYPERGLYCEMIA; HYPERTENSION; HYPOXEMIA; INSULIN RESISTANCE; INTERMITTENT HYPOXIA; LIPOLYSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; OXYGEN TISSUE LEVEL; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REM SLEEP; REPERFUSION INJURY; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP FRAGMENTATION; SYMPATHETIC TONE; TISSUE OXYGENATION;

EID: 84920896801     PISSN: 14469235     EISSN: 14798425     Source Type: Journal    
DOI: 10.1111/sbr.12078     Document Type: Article

References (228)

1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N. Engl. J. Med. 1993; 328: 1230-1235.
2. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am. J. Epidemiol. 2013; 177: 1006-1014.
3. Young T, Palta M, Dempsey J, Peppard PE, Nieto FJ, Hla KM. Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study. WMJ 2009; 108: 246-249.
4. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur. Heart J. 2004; 25: 735-741.
5. Bonsignore MR, Borel AL, Machan E, Grunstein R. Sleep apnoea and metabolic dysfunction. Eur. Respir. Rev. 2013; 22 (129): 353-364.
6. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001; 285: 2486-2497.
7. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
8. Harman D. Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 1956; 11: 298-300.
9. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004; 27: 123-128.
10. Barcelo A, Miralles C, Barbe F, Vila M, Pons S, Agusti AG. Abnormal lipid peroxidation in patients with sleep apnoea. Eur. Respir. J. 2000; 16: 644-647.
11. Tóthová L, Hodosy J, Mucska I, Celec P. Salivary markers of oxidative stress in patients with obstructive sleep apnea treated with continuous positive airway pressure. Sleep Breath. 2013; [Epub ahead of print].
12. Carpagnano GE, Kharitonov SA, Resta O, Foschino-Barbaro MP, Gramiccioni E, Barnes PJ. 8-Isoprostane, a marker of oxidative stress, is increased in exhaled breath condensate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 2003; 124: 1386-1392.
13. Itzhaki S, Dorchin H, Clark G, Lavie L, Lavie P, Pillar G. The effects of 1-year treatment with a herbst mandibular advancement splint on obstructive sleep apnea, oxidative stress, and endothelial function. Chest 2007; 131: 740-749.
14. Yang XH, Liu X, Shang J, Liu HG, Xu YJ. Correlation between the serum level of advanced oxidation protein products and the cognitive function in patients with obstructive sleep apnea hypopnea syndrome. Zhonghua Jie He He Hu Xi Za Zhi 2013; 36: 274-279.
15. Celec P, Hodosy J, Behuliak M etal. Oxidative and carbonyl stress in patients with obstructive sleep apnea treated with continuous positive airway pressure. Sleep Breath. 2012; 16: 393-398.
16. Yamauchi M, Nakano H, Maekawa J etal. Oxidative stress in obstructive sleep apnea. Chest 2005; 127: 1674-1679.
17. Christou K, Moulas AN, Pastaka C, Gourgoulianis KI. Antioxidant capacity in obstructive sleep apnea patients. Sleep Med. 2003; 4: 225-228.
18. Schulz R, Mahmoudi S, Hattar K etal. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am. J. Respir. Crit. Care Med. 2000; 162 (2 Pt 1): 566-570.
19. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am. J. Respir. Crit. Care Med. 2002; 165: 934-939.
20. Lavie L, Lavie P. Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur. Respir. J. 2009; 33: 1467-1484.
21. Dumitrascu R, Heitmann J, Seeger W, Weissmann N, Schulz R. Obstructive sleep apnea, oxidative stress and cardiovascular disease: lessons from animal studies. Oxid. Med. Cell Longev. 2013; 2013: 234631.
22. Xu W, Chi L, Row BW etal. Increased oxidative stress is associated with chronic intermittent hypoxia-mediated brain cortical neuronal cell apoptosis in a mouse model of sleep apnea. Neuroscience 2004; 126: 313-323.
23. Zhan G, Serrano F, Fenik P etal. NADPH oxidase mediates hypersomnolence and brain oxidative injury in a murine model of sleep apnea. Am. J. Respir. Crit. Care Med. 2005; 172: 921-929.
24. Greenberg H, Ye X, Wilson D, Htoo AK, Hendersen T, Liu SF. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem. Biophys. Res. Commun. 2006; 343: 591-596.
25. Esteva S, Pedret R, Fort N, Torrella JR, Pages T, Viscor G. Oxidative stress status in rats after intermittent exposure to hypobaric hypoxia. Wilderness Environ. Med. 2010; 21: 325-331.
26. Jun J, Savransky V, Nanayakkara A etal. Intermittent hypoxia has organ-specific effects on oxidative stress. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008; 295: R1274-1281.
27. Huckabee WE. Relationships of pyruvate and lactate during anaerobic metabolism. III. Effect of breathing low-oxygen gases. J. Clin. Invest. 1958; 37: 264-271.
28. Buckley L, Beres L. Studies on the stability of tritium-labeled polyuridylic acid and polyadenylic acid. Anal. Biochem. 1978; 84: 319-323.
29. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med. 1985; 312: 159-163.
30. Kerrigan CL, Stotland MA. Ischemia reperfusion injury: a review. Microsurgery 1993; 14: 165-175.
31. Jefferson JA, Escudero E, Johnson RJ, Swenson ER, Hurtado A. Increased oxidative stress at altitude. Chest 2014; 145: 423.
32. Siervo M, Riley HL, Fernandez BO etal. Effects of prolonged exposure to hypobaric hypoxia on oxidative stress, inflammation and gluco-insular regulation: the not-so-sweet price for good regulation. PLoS One 2014; 9: e94915.
33. Pichler Hefti J, Sonntag D, Hefti U etal. Oxidative stress in hypobaric hypoxia and influence on vessel-tone modifying mediators. High Alt. Med. Biol. 2013; 14: 273-279.
34. Behn C, Araneda OF, Llanos AJ, Celedon G, Gonzalez G. Hypoxia-related lipid peroxidation: evidences, implications and approaches. Respir. Physiol. Neurobiol. 2007; 158: 143-150.
35. Kehrer JP, Lund LG. Cellular reducing equivalents and oxidative stress. Free Radic. Biol. Med. 1994; 17: 65-75.
36. Mesarwi O, Polak J, Jun J, Polotsky VY. Sleep disorders and the development of insulin resistance and obesity. Endocrinol. Metab. Clin. North Am. 2013; 42: 617-634.
37. Jun JC, Drager LF, Najjar SS etal. Effects of sleep apnea on nocturnal free fatty acids in subjects with heart failure. Sleep 2011; 34: 1207-1213.
38. Egan BM, Lu G, Greene EL. Vascular effects of non-esterified fatty acids: implications for the cardiovascular risk factor cluster. Prostaglandins Leukot. Essent. Fatty Acids 1999; 60: 411-420.
39. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr. Diab. Rep. 2006; 6: 177-181.
40. Wang HL, Wang Y, Zhang Y etal. Changes in plasma angiotensin II and circadian rhythm of blood pressure in hypertensive patients with sleep apnea syndrome before and after treatment. Chin. Med. Sci. J. 2011; 26: 9-13.
41. Kizawa T, Nakamura Y, Takahashi S, Sakurai S, Yamauchi K, Inoue H. Pathogenic role of angiotensin II and oxidised LDL in obstructive sleep apnoea. Eur. Respir. J. 2009; 34: 1390-1398.
42. Foster GE, Hanly PJ, Ahmed SB, Beaudin AE, Pialoux V, Poulin MJ. Intermittent hypoxia increases arterial blood pressure in humans through a Renin-Angiotensin system-dependent mechanism. Hypertension 2010; 56: 369-377.
43. Fletcher EC. Invited review: physiological consequences of intermittent hypoxia: systemic blood pressure. J. Appl. Physiol. 2001; 90: 1600-1605.
44. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J. Hum. Hypertens. 2007; 21: 20-27.
45. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994; 74: 1141-1148.
46. Henriksen EJ, Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J. Cell. Physiol. 2003; 196: 171-179.
47. Egan BM. Overnight rostral fluid shift and obstructive sleep apnea in treatment resistant hypertension: connecting the dots clarifies the picture. Hypertension 2010; 56: 1040-1041.
48. Lacroix S, Rosiers CD, Tardif JC, Nigam A. The role of oxidative stress in postprandial endothelial dysfunction. Nutr. Res. 2012; 25: 288-301.
49. Vincent HK, Taylor AG. Biomarkers and potential mechanisms of obesity-induced oxidant stress in humans. Int. J. Obes. (Lond.) 2006; 30: 400-418.
50. Pitocco D, Tesauro M, Alessandro R, Ghirlanda G, Cardillo C. Oxidative stress in diabetes: implications for vascular and other complications. Int. J. Mol. Sci. 2013; 14: 21525-21550.
51. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells - implications in cardiovascular disease. Braz. J. Med. Biol. Res. 2004; 37: 1263-1273.
52. Ceriello A. Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 2008; 31 (Suppl 2): S181-184.
53. Appel LJ, Moore TJ, Obarzanek E etal. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N. Engl. J. Med. 1997; 336: 1117-1124.
54. John JH, Ziebland S, Yudkin P, Roe LS, Neil HA. Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial. Lancet 2002; 359: 1969-1974.
55. Galley HF, Thornton J, Howdle PD, Walker BE, Webster NR. Combination oral antioxidant supplementation reduces blood pressure. Clin. Sci. (Lond) 1997; 92: 361-365.
56. Furukawa S, Fujita T, Shimabukuro M etal. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004; 114: 1752-1761.
57. Groop LC, Saloranta C, Shank M, Bonadonna RC, Ferrannini E, DeFronzo RA. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1991; 72: 96-107.
58. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668.
59. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 2002; 277: 1531-1537.
60. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid. Redox Signal. 2005; 7: 1040-1052.
61. Mahadev K, Motoshima H, Wu X etal. The NAD(P)H oxidase homolog Nox4 modulates insulin-stimulated generation of H2O2 and plays an integral role in insulin signal transduction. Mol. Cell. Biol. 2004; 24: 1844-1854.
62. Gardner CD, Eguchi S, Reynolds CM, Eguchi K, Frank GD, Motley ED. Hydrogen peroxide inhibits insulin signaling in vascular smooth muscle cells. Exp. Biol. Med. (Maywood) 2003; 228: 836-842.
63. Maddux BA, See W, Lawrence JC, Jr, Goldfine AL, Goldfine ID, Evans JL. Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by mircomolar concentrations of alpha-lipoic acid. Diabetes 2001; 50: 404-410.
64. Patel S, Van Der Kaay J, Sutherland C. Insulin regulation of hepatic insulin-like growth factor-binding protein-1 (IGFBP-1) gene expression and mammalian target of rapamycin (mTOR) signalling is impaired by the presence of hydrogen peroxide. Biochem. J. 2002; 365 (Pt 2): 537-545.
65. Eriksson JW. Metabolic stress in insulin's target cells leads to ROS accumulation - a hypothetical common pathway causing insulin resistance. FEBS Lett. 2007; 581: 3734-3742.
66. Bloch-Damti A, Bashan N. Proposed mechanisms for the induction of insulin resistance by oxidative stress. Antioxid. Redox Signal. 2005; 7: 1553-1567.
67. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 2006; 55 (Suppl 2): S9-S15.
68. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr. Rev. 2008; 29: 351-366.
69. Du X, Stocklauser-Farber K, Rosen P. Generation of reactive oxygen intermediates, activation of NF-kappaB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? Free Radic. Biol. Med. 1999; 27: 752-763.
70. Gupta S, Chough E, Daley J etal. Hyperglycemia increases endothelial superoxide that impairs smooth muscle cell Na+-K+-ATPase activity. Am. J. Physiol. Cell Physiol. 2002; 282: C560-566.
71. Jacob S, Henriksen EJ, Tritschler HJ, Augustin HJ, Dietze GJ. Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Exp. Clin. Endocrinol. Diabetes 1996; 104: 284-288.
72. Jacob S, Ruus P, Hermann R etal. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic. Biol. Med. 1999; 27: 309-314.
73. Fulghesu AM, Ciampelli M, Muzj G etal. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil. Steril. 2002; 77: 1128-1135.
74. Walden DL, McCutchan HJ, Enquist EG etal. Neutrophils accumulate and contribute to skeletal muscle dysfunction after ischemia-reperfusion. Am. J. Physiol. 1990; 259 (6 Pt 2): H1809-1812.
75. American Diabetes Association. Nutrition Recommendations and Interventions for Diabetes: a position statement of the American Diabetes Association. Diabetes Care 2007; 30 (Suppl 1): S48-65.
76. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297: 842-857.
77. Haidara MA, Yassin HZ, Zakula Z, Mikhailidis DP, Isenovic ER. Diabetes and antioxidants: myth or reality? Curr. Vasc. Pharmacol. 2010; 8: 661-672.
78. Moyer MW. The myth of antioxidants. Sci. Am. 2013; 308: 62-67.
79. Steiropoulos P, Papanas N, Nena E, Maltezos E, Bouros D. Continuous positive airway pressure treatment in patients with sleep apnoea: does it really improve glucose metabolism? Curr. Diabetes Rev. 2010; 6: 156-166.
80. Murri M, Garcia-Delgado R, Alcazar-Ramirez J etal. Continuous positive airway pressure therapy reduces oxidative stress markers and blood pressure in sleep apnea-hypopnea syndrome patients. Biol. Trace Elem. Res. 2011; 143: 1289-1301.
81. Buchner NJ, Quack I, Woznowski M, Stahle C, Wenzel U, Rump LC. Microvascular endothelial dysfunction in obstructive sleep apnea is caused by oxidative stress and improved by continuous positive airway pressure therapy. Respiration 2011; 82: 409-417.
82. Grebe M, Eisele HJ, Weissmann N etal. Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 2006; 173: 897-901.
83. El Solh AA, Saliba R, Bosinski T, Grant BJ, Berbary E, Miller N. Allopurinol improves endothelial function in sleep apnoea: a randomised controlled study. Eur. Respir. J. 2006; 27: 997-1002.
84. Svendsen M, Blomhoff R, Holme I, Tonstad S. The effect of an increased intake of vegetables and fruit on weight loss, blood pressure and antioxidant defense in subjects with sleep related breathing disorders. Eur. J. Clin. Nutr. 2007; 61: 1301-1311.
85. Sadasivam K, Patial K, Vijayan VK, Ravi K. Anti-oxidant treatment in obstructive sleep apnoea syndrome. Indian J. Chest Dis. Allied Sci. 2011; 53: 153-162.
86. Tovar S, Paeger L, Hess S etal. K(ATP)-channel-dependent regulation of catecholaminergic neurons controls BAT sympathetic nerve activity and energy homeostasis. Cell Metab. 2013; 18: 445-455.
87. Gompf HS, Mathai C, Fuller PM etal. Locus ceruleus and anterior cingulate cortex sustain wakefulness in a novel environment. J. Neurosci. 2010; 30: 14543-14551.
88. Patterson ZR, Abizaid A. Stress induced obesity: lessons from rodent models of stress. Front. Neurosci. 2013; 7: 130.
89. Kyrou I, Tsigos C. Stress hormones: physiological stress and regulation of metabolism. Curr. Opin. Pharmacol. 2009; 9: 787-793.
90. Narkiewicz K, van de Borne PJ, Cooley RL, Dyken ME, Somers VK. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98: 772-776.
91. Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J. Appl. Physiol. 1989; 67: 2101-2106.
92. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J. Clin. Invest. 1995; 96: 1897-1904.
93. Baruzzi A, Riva R, Cirignotta F, Zucconi M, Cappelli M, Lugaresi E. Atrial natriuretic peptide and catecholamines in obstructive sleep apnea syndrome. Sleep 1991; 14: 83-86.
94. Marrone O, Riccobono L, Salvaggio A, Mirabella A, Bonanno A, Bonsignore MR. Catecholamines and blood pressure in obstructive sleep apnea syndrome. Chest 1993; 103: 722-727.
95. Ziegler MG, Mills PJ, Loredo JS, Ancoli-Israel S, Dimsdale JE. Effect of continuous positive airway pressure and placebo treatment on sympathetic nervous activity in patients with obstructive sleep apnea. Chest 2001; 120: 887-893.
96. Prabhakar NR, Kumar GK, Peng YJ. Sympatho-adrenal activation by chronic intermittent hypoxia. J. Appl. Physiol. 2012; 113: 1304-1310.
97. Gonzalez-Martin MC, Vega-Agapito MV, Conde SV etal. Carotid body function and ventilatory responses in intermittent hypoxia. Evidence for anomalous brainstem integration of arterial chemoreceptor input. J. Cell. Physiol. 2011; 226: 1961-1969.
98. Dick TE, Hsieh YH, Wang N, Prabhakar N. Acute intermittent hypoxia increases both phrenic and sympathetic nerve activities in the rat. Exp. Physiol. 2007; 92: 87-97.
99. Greenberg HE, Sica A, Batson D, Scharf SM. Chronic intermittent hypoxia increases sympathetic responsiveness to hypoxia and hypercapnia. J. Appl. Physiol. 1999; 86: 298-305.
100. Huang J, Lusina S, Xie T etal. Sympathetic response to chemostimulation in conscious rats exposed to chronic intermittent hypoxia. Respir. Physiol. Neurobiol. 2009; 166: 102-106.
101. Marcus NJ, Li YL, Bird CE, Schultz HD, Morgan BJ. Chronic intermittent hypoxia augments chemoreflex control of sympathetic activity: role of the angiotensin II type 1 receptor. Respir. Physiol. Neurobiol. 2010; 171: 36-45.
102. Narkiewicz K, Kato M, Phillips BG, Pesek CA, Davison DE, Somers VK. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation 1999; 100: 2332-2335.
103. Peng YJ, Overholt JL, Kline D, Kumar GK, Prabhakar NR. Induction of sensory long-term facilitation in the carotid body by intermittent hypoxia: implications for recurrent apneas. Proc. Natl Acad. Sci. U.S.A. 2003; 100: 10073-10078.
104. Peng YJ, Rennison J, Prabhakar NR. Intermittent hypoxia augments carotid body and ventilatory response to hypoxia in neonatal rat pups. J. Appl. Physiol. 2004; 97: 2020-2025.
105. Peng YJ, Yuan G, Ramakrishnan D etal. Heterozygous HIF-1alpha deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J. Physiol. 2006; 577 (Pt 2): 705-716.
106. Peng YJ, Yuan G, Jacono FJ, Kumar GK, Prabhakar NR. 5-HT evokes sensory long-term facilitation of rodent carotid body via activation of NADPH oxidase. J. Physiol. 2006; 576 (Pt 1): 289-295.
107. Peng YJ, Nanduri J, Yuan G etal. NADPH oxidase is required for the sensory plasticity of the carotid body by chronic intermittent hypoxia. J. Neurosci. 2009; 29: 4903-4910.
108. Prabhakar NR, Dick TE, Nanduri J, Kumar GK. Systemic, cellular and molecular analysis of chemoreflex-mediated sympathoexcitation by chronic intermittent hypoxia. Exp. Physiol. 2007; 92: 39-44.
109. Prabhakar NR, Kumar GK, Nanduri J. Intermittent hypoxia augments acute hypoxic sensing via HIF-mediated ROS. Respir. Physiol. Neurobiol. 2010; 174: 230-234.
110. Bao G, Metreveli N, Li R, Taylor A, Fletcher EC. Blood pressure response to chronic episodic hypoxia: role of the sympathetic nervous system. J. Appl. Physiol. 1997; 83: 95-101.
111. Kumar GK, Rai V, Sharma SD etal. Chronic intermittent hypoxia induces hypoxia-evoked catecholamine efflux in adult rat adrenal medulla via oxidative stress. J. Physiol. 2006; 575 (Pt 1): 229-239.
112. Fletcher EC, Lesske J, Behm R, Miller CC 3rd Stauss H, Unger T. Carotid chemoreceptors, systemic blood pressure, and chronic episodic hypoxia mimicking sleep apnea. J. Appl. Physiol. 1992; 72: 1978-1984.
113. Knight WD, Little JT, Carreno FR, Toney GM, Mifflin SW, Cunningham JT. Chronic intermittent hypoxia increases blood pressure and expression of FosB/DeltaFosB in central autonomic regions. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011; 301: R131-139.
114. Somers VK, Mark AL, Abboud FM. Sympathetic activation by hypoxia and hypercapnia-implications for sleep apnea. Clin. Exp. Hypertens. A 1988; 10 (Suppl 1): 413-422.
115. Narkiewicz K, Somers VK. Sympathetic nerve activity in obstructive sleep apnoea. Acta Physiol. Scand. 2003; 177: 385-390.
116. Schneider H, Schaub CD, Chen CA etal. Neural and local effects of hypoxia on cardiovascular responses to obstructive apnea. J. Appl. Physiol. 2000; 88: 1093-1102.
117. Louis M, Punjabi NM. Effects of acute intermittent hypoxia on glucose metabolism in awake healthy volunteers. J. Appl. Physiol. 2009; 106: 1538-1544.
118. Oltmanns KM, Gehring H, Rudolf S etal. Hypoxia causes glucose intolerance in humans. Am. J. Respir. Crit. Care Med. 2004; 169: 1231-1237.
119. Peltonen GL, Scalzo RL, Schweder MM etal. Sympathetic inhibition attenuates hypoxia induced insulin resistance in healthy adult humans. J. Physiol. 2012; 590 (Pt 11): 2801-2809.
120. Lesske J, Fletcher EC, Bao G, Unger T. Hypertension caused by chronic intermittent hypoxia-influence of chemoreceptors and sympathetic nervous system. J. Hypertens. 1997; 15 (12 Pt 2): 1593-1603.
121. Tamisier R, Pepin JL, Remy J etal. 14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. Eur. Respir. J. 2011; 37: 119-128.
122. Gottlieb DJ, Punjabi NM, Mehra R etal. CPAP versus oxygen in obstructive sleep apnea. N. Engl. J. Med. 2014; 370: 2276-2285.
123. Barth E, Albuszies G, Baumgart K etal. Glucose metabolism and catecholamines. Crit. Care Med. 2007; 35 (9 Suppl): S508-518.
124. Ziegler MG, Elayan H, Milic M, Sun P, Gharaibeh M. Epinephrine and the metabolic syndrome. Curr. Hypertens. Rep. 2012; 14: 1-7.
125. Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia. Lancet 2009; 373: 1798-1807.
126. Nobin A, Baumgarten HG, Falck B, Ingemansson S, Moghimzadeh E, Rosengren E. Organization of the sympathetic innervation in liver tissue from monkey and man. Cell Tissue Res. 1978; 195: 371-380.
127. Metz W, Forssmann WG. Innervation of the liver in guinea pig and rat. Anat. Embryol. 1980; 160: 239-252.
128. Hartmann H, Beckh K, Jungermann K. Direct control of glycogen metabolism in the perfused rat liver by the sympathetic innervation. Eur. J. Biochem. 1982; 123: 521-526.
129. Henriksen JH, Moller S, Ring-Larsen H, Christensen NJ. The sympathetic nervous system in liver disease. J. Hepatol. 1998; 29: 328-341.
130. Oben JA, Roskams T, Yang S etal. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut 2004; 53: 438-445.
131. Deibert DC, DeFronzo RA. Epinephrine-induced insulin resistance in man. J. Clin. Invest. 1980; 65: 717-721.
132. Szollosi A, Nenquin M, Henquin JC. Pharmacological stimulation and inhibition of insulin secretion in mouse islets lacking ATP-sensitive K+ channels. Br. J. Pharmacol. 2010; 159: 669-677.
133. Skoglund G, Lundquist I, Ahren B. Effects of alpha 1- and alpha 2-adrenoceptor stimulation and blockade on plasma insulin levels in the mouse. Pancreas 1986; 1: 415-420.
134. Ahren B, Lundquist I. Effects of alpha-adrenoceptor blockade by phentolamine on basal and stimulated insulin secretion in the mouse. Acta Physiol. Scand. 1985; 125: 211-217.
135. Liggett SB. alpha2A-adrenergic receptors in the genetics, pathogenesis, and treatment of type 2 diabetes. Sci. Transl. Med. 2009; 1: 12ps5.
136. Ruohonen ST, Ruohonen S, Gilsbach R, Savontaus E, Scheinin M, Hein L. Involvement of alpha2-adrenoceptor subtypes A and C in glucose homeostasis and adrenaline-induced hyperglycaemia. Neuroendocrinology 2012; 96: 51-59.
137. Lerner RL, Porte D, Jr. Epinephrine: selective inhibition of the acute insulin response to glucose. J. Clin. Invest. 1971; 50: 2453-2457.
138. Pessina AC, Ciccariello L, Perrone F etal. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr. Metab. Cardiovasc. Dis. 2006; 16: 137-147.
139. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. J. Cardiovasc. Pharmacol. 2005; 45: 599-604.
140. Barzilay JI, Davis BR, Bettencourt J etal. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J. Clin. Hypertens. (Greenwich) 2004; 6: 116-125.
141. DiBona GF. Sympathetic nervous system and hypertension. Hypertension 2013; 61: 556-560.
142. Krum H, Schlaich MP, Sobotka PA etal. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014; 383: 622-629.
143. Brotman DJ, Girod JP. The metabolic syndrome: a tug-of-war with no winner. Cleve. Clin. J. Med. 2002; 69: 990-994.
144. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-788.
145. Kulick D, Liu DK. Isolation and characterization of polyploid nuclei of R3230AC mammary adenocarcinoma and comparison with normal mammary nuclei. Cancer Res. 1981; 41: 3907-3912.
146. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim. Biophys. Acta 2010; 1801: 209-214.
147. Ischebeck H, Kuske V. Proceedings: multiple meningiomas. Acta Neurochir. (Wien) 1975; 31: 278.
148. Eltringham WK, Jenny ME, Morgan AP. Metabolic and tissue effects of prolonged catecholamine infusion. Postgrad. Med. J. 1969; 45: 545-549.
149. Kim JK, Kim YJ, Fillmore JJ etal. Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 2001; 108: 437-446.
150. Kim JK, Fillmore JJ, Sunshine MJ etal. PKC-theta knockout mice are protected from fat-induced insulin resistance. J. Clin. Invest. 2004; 114: 823-827.
151. Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care 2007; 10: 142-148.
152. Sniderman AD, Cianflone K. Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler. Thromb. 1993; 13: 629-636.
153. Pervanidou P, Chrousos GP. Metabolic consequences of stress during childhood and adolescence. Metabolism 2012; 61: 611-619.
154. Golden SH. A review of the evidence for a neuroendocrine link between stress, depression and diabetes mellitus. Curr. Diabetes Rev. 2007; 3: 252-259.
155. Abboud F, Kumar R. Obstructive sleep apnea and insight into mechanisms of sympathetic overactivity. J. Clin. Invest. 2014; 124: 1454-1457.
156. Barcelo A, Pierola J, de la Pena M etal. Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnoea. Eur. Respir. J. 2011; 37: 1418-1423.
157. Epstein LJ, Kristo D, Strollo PJ, Jr. etal. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J. Clin. Sleep Med. 2009; 5: 263-276.
158. Henrion J, Colin L, Schapira M, Heller FR. Hypoxic hepatitis caused by severe hypoxemia from obstructive sleep apnea. J. Clin. Gastroenterol. 1997; 24: 245-249.
159. Trakada G, Gogos C, Tsiamita M, Siagris D, Goumas P, Spiropoulos K. A case of ischemic hepatitis. Sleep Breath. 2004; 8: 155-159.
160. Lentini S, Manka R, Scholtyssek S, Stoffel-Wagner B, Luderitz B, Tasci S. Creatine phosphokinase elevation in obstructive sleep apnea syndrome: an unknown association? Chest 2006; 129: 88-94.
161. Ucar ZZ, Taymaz Z, Erbaycu AE, Kirakli C, Tuksavul F, Guclu SZ. Nocturnal hypoxia and arterial lactate levels in sleep-related breathing disorders. South. Med. J. 2009; 102: 693-700.
162. Hira HS, Shukla A, Kaur A, Kapoor S. Serum uric acid and lactate levels among patients with obstructive sleep apnea syndrome: which is a better marker of hypoxemia? Ann. Saudi Med. 2012; 32: 37-42.
163. Vanuxem D, Badier M, Guillot C, Delpierre S, Jahjah F, Vanuxem P. Impairment of muscle energy metabolism in patients with sleep apnoea syndrome. Respir. Med. 1997; 91: 551-557.
164. Choi JB, Loredo JS, Norman D etal. Does obstructive sleep apnea increase hematocrit? Sleep Breath. 2006; 10: 155-160.
165. King AJ, Eyre T, Littlewood T. Obstructive sleep apnoea does not lead to clinically significant erythrocytosis. BMJ 2013; 347: f7340.
166. Solmaz S, Duksal F, Ganidagli S. Is obstructive sleep apnoea syndrome really one of the causes of secondary polycythaemia? Hematology 2014; [Epub ahead of print].
167. Reinke C, Bevans-Fonti S, Drager LF, Shin MK, Polotsky VY. Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes. J. Appl. Physiol. 2011; 111: 881-890.
168. Almendros I, Farre R, Planas AM etal. Tissue oxygenation in brain, muscle, and fat in a rat model of sleep apnea: differential effect of obstructive apneas and intermittent hypoxia. Sleep 2011; 34: 1127-1133.
169. Semenza GL. Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor 1. Exp. Physiol. 2006; 91: 803-806.
170. Jaakkola P, Mole DR, Tian YM etal. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-472.
171. Yuan G, Nanduri J, Khan S, Semenza GL, Prabhakar NR. Induction of HIF-1alpha expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J. Cell. Physiol. 2008; 217: 674-685.
172. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 2001; 13: 167-171.
173. Kaczmarek E, Bakker JP, Clarke DN etal. Molecular biomarkers of vascular dysfunction in obstructive sleep apnea. PLoS One 2013; 8: e70559.
174. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-2667.
175. da Rosa DP, Forgiarini LF, Baronio D, Feijo CA, Martinez D, Marroni NP. Simulating sleep apnea by exposure to intermittent hypoxia induces inflammation in the lung and liver. Mediators Inflamm. 2012; 2012: 879419.
176. Yuan G, Nanduri J, Bhasker CR, Semenza GL, Prabhakar NR. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J. Biol. Chem. 2005; 280: 4321-4328.
177. Young PM, Rose MS, Sutton JR, Green HJ, Cymerman A, Houston CS. Operation Everest II: plasma lipid and hormonal responses during a simulated ascent of Mt. Everest. J. Appl. Physiol. 1989; 66: 1430-1435.
178. Gautier H. Interactions among metabolic rate, hypoxia, and control of breathing. J. Appl. Physiol. 1996; 81: 521-527.
179. Jun JC, Shin MK, Yao Q etal. Acute hypoxia induces hypertriglyceridemia by decreasing plasma triglyceride clearance in mice. Am. J. Physiol. Endocrinol. Metab. 2012; 303: E377-388.
180. Jun JC, Shin MK, Yao Q, Devera R, Fonti-Bevans S, Polotsky VY. Thermoneutrality modifies the impact of hypoxia on lipid metabolism. Am. J. Physiol. Endocrinol. Metab. 2013; 304: E424-435.
181. Pasarica M, Rood J, Ravussin E, Schwarz JM, Smith SR, Redman LM. Reduced oxygenation in human obese adipose tissue is associated with impaired insulin suppression of lipolysis. J. Clin. Endocrinol. Metab. 2010; 95: 4052-4055.
182. Pasarica M, Sereda OR, Redman LM etal. Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response. Diabetes 2009; 58: 718-725.
183. Hosogai N, Fukuhara A, Oshima K etal. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007; 56: 901-911.
184. He Q, Gao Z, Yin J, Zhang J, Yun Z, Ye J. Regulation of HIF-1{alpha} activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia. Am. J. Physiol. Endocrinol. Metab. 2011; 300: E877-885.
185. Halberg N, Khan T, Trujillo ME etal. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol. Cell. Biol. 2009; 29: 4467-4483.
186. Jiang C, Qu A, Matsubara T etal. Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes 2011; 60: 2484-2495.
187. Magalang UJ, Cruff JP, Rajappan R etal. Intermittent hypoxia suppresses adiponectin secretion by adipocytes. Exp. Clin. Endocrinol. Diabetes 2009; 117: 129-134.
188. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch. 2007; 455: 479-492.
189. Wang B, Wood IS, Trayhurn P. Hypoxia induces leptin gene expression and secretion in human preadipocytes: differential effects of hypoxia on adipokine expression by preadipocytes. J. Endocrinol. 2008; 198: 127-134.
190. Boppidi H, Daram SR. Nonalcoholic fatty liver disease: hepatic manifestation of obesity and the metabolic syndrome. Postgrad. Med. 2008; 120: E01-7.
191. Baze MM, Schlauch K, Hayes JP. Gene expression of the liver in response to chronic hypoxia. Physiol. Genomics 2010; 41: 275-288.
192. Piguet AC, Stroka D, Zimmermann A, Dufour JF. Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. Clin. Sci. (Lond.) 2010; 118: 401-410.
193. Moon JO, Welch TP, Gonzalez FJ, Copple BL. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2009; 296 (3): G582-592.
194. Copple BL, Bai S, Moon JO. Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic Kupffer cells. Hepatol. Res. 2010; 40: 530-539.
195. Copple BL, Bai S, Burgoon LD, Moon JO. Hypoxia-inducible factor-1 alpha regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int. 2011; 31: 230-244.
196. Okamoto R, Hatani M, Tsukitani M etal. The effect of oxygen on the development of atherosclerosis in WHHL rabbits. Atherosclerosis 1983; 47: 47-53.
197. Martin JF, Booth RF, Moncada S. Arterial wall hypoxia following thrombosis of the vasa vasorum is an initial lesion in atherosclerosis. Eur. J. Clin. Invest. 1991; 21: 355-359.
198. Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho G. Early signs of atherosclerosis in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 2005; 172: 613-618.
199. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 2007; 176: 706-712.
200. Savransky V, Nanayakkara A, Li J etal. Chronic intermittent hypoxia induces atherosclerosis. Am. J. Respir. Crit. Care Med. 2007; 175: 1290-1297.
201. Jun J, Reinke C, Bedja D etal. Effect of intermittent hypoxia on atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2010; 209: 381-386.
202. Drager LF, Yao Q, Hernandez KL etal. Chronic intermittent hypoxia induces atherosclerosis via activation of adipose angiopoietin-like 4. Am. J. Respir. Crit. Care Med. 2013; 188: 240-248.
203. Kayser B, Verges S. Hypoxia, energy balance and obesity: from pathophysiological mechanisms to new treatment strategies. Obes. Rev. 2013; 14: 579-592.
204. Mackenzie R, Maxwell N, Castle P, Elliott B, Brickley G, Watt P. Intermittent exercise with and without hypoxia improves insulin sensitivity in individuals with type 2 diabetes. J. Clin. Endocrinol. Metab. 2012; 97: E546-555.
205. Mackenzie R, Maxwell N, Castle P, Brickley G, Watt P. Acute hypoxia and exercise improve insulin sensitivity (S(I) (2*)) in individuals with type 2 diabetes. Diabetes Metab. Res. Rev. 2011; 27: 94-101.
206. Lee EJ, Alonso LC, Stefanovski D etal. Time-dependent changes in glucose and insulin regulation during intermittent hypoxia and continuous hypoxia. Eur. J. Appl. Physiol. 2013; 113: 467-478.
207. Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am. J. Epidemiol. 2004; 160: 521-530.
208. Mehta V, Vasu TS, Phillips B, Chung F. Obstructive sleep apnea and oxygen therapy: a systematic review of the literature and meta-analysis. J. Clin. Sleep Med. 2013; 9: 271-279.
209. Pokorski M, Jernajczyk U. Nocturnal oxygen enrichment in sleep apnoea. J. Int. Med. Res. 2000; 28: 1-8.
210. Norman D, Loredo JS, Nelesen RA etal. Effects of continuous positive airway pressure versus supplemental oxygen on 24-hour ambulatory blood pressure. Hypertension 2006; 47: 840-845.
211. Mills PJ, Kennedy BP, Loredo JS, Dimsdale JE, Ziegler MG. Effects of nasal continuous positive airway pressure and oxygen supplementation on norepinephrine kinetics and cardiovascular responses in obstructive sleep apnea. J. Appl. Physiol. 2006; 100: 343-348.
212. Fava C, Dorigoni S, Dalle Vedove F etal. Effect of CPAP on blood pressure in patients with OSA/hypopnea a systematic review and meta-analysis. Chest 2014; 145: 762-771.
213. Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. Chest 2010; 137: 95-101.
214. Tasali E, Ip MS. Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc. Am. Thorac. Soc. 2008; 5: 207-217.
215. Carrington MJ, Trinder J. Blood pressure and heart rate during continuous experimental sleep fragmentation in healthy adults. Sleep 2008; 31: 1701-1712.
216. Silvani A, Dampney RA. Central control of cardiovascular function during sleep. Am. J. Physiol. Heart Circ. Physiol. 2013; 305: H1683-1692.
217. van den Berg JF, Knvistingh Neven A, Tulen JH etal. Actigraphic sleep duration and fragmentation are related to obesity in the elderly: the Rotterdam Study. Int. J. Obes. (Lond.) 2008; 32: 1083-1090.
218. Lofaso F, Coste A, Gilain L, Harf A, Guilleminault C, Goldenberg F. Sleep fragmentation as a risk factor for hypertension in middle-aged nonapneic snorers. Chest 1996; 109: 896-900.
219. Grahnstedt S, Ursin R. Platform sleep deprivation affects deep slow wave sleep in addition to REM sleep. Behav. Brain Res. 1985; 18: 233-239.
220. Hilakivi I, Peder M, Elomaa E, Johansson G. Validation of the cuff pedestal technique for rapid eye movement sleep (REMs) deprivation by electrophysiological recordings. Physiol. Behav. 1984; 32: 945-947.
221. Mendelson WB, Guthrie RD, Frederick G, Wyatt RJ. The flower pot technique of rapid eye movement (REM) sleep deprivation. Pharmacol. Biochem. Behav. 1974; 2: 553-556.
222. Brooks D, Horner RL, Kimoff RJ, Kozar LF, Render-Teixeira CL, Phillipson EA. Effect of obstructive sleep apnea versus sleep fragmentation on responses to airway occlusion. Am. J. Respir. Crit. Care Med. 1997; 155: 1609-1617.
223. Brooks D, Horner RL, Kozar LF, Render-Teixeira CL, Phillipson EA. Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. J. Clin. Invest. 1997; 99: 106-109.
224. Polotsky VY, Rubin AE, Balbir A etal. Intermittent hypoxia causes REM sleep deficits and decreases EEG delta power in NREM sleep in the C57BL/6J mouse. Sleep Med. 2006; 7: 7-16.
225. Barf RP, Meerlo P, Scheurink AJ. Chronic sleep disturbance impairs glucose homeostasis in rats. Int. J. Endocrinol. 2010; 2010: 819414.
226. Zhang SX, Khalyfa A, Wang Y etal. Sleep fragmentation promotes NADPH oxidase 2-mediated adipose tissue inflammation leading to insulin resistance in mice. Int. J. Obes. (Lond.) 2014; 38: 619-624.
227. Baud MO, Magistretti PJ, Petit JM. Sustained sleep fragmentation affects brain temperature, food intake and glucose tolerance in mice. J. Sleep Res. 2013; 22: 3-12.
228. Wang Y, Carreras A, Lee S etal. Chronic sleep fragmentation promotes obesity in young adult mice. Obesity 2014; 22: 758-762.